Sugi Predict

Sugi Predict / Compounds / SCHEMBL2798730

SCHEMBL2798730

SCHEMBL2798730

Cc1nn(C2CCN(C(=O)OC(C)(C)C)CC2)c(C)c1Br

nearest known ligand 0.46

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ NR3C1 P04150 3/20 0.46
▸ GPR119 Q8TDV5 6/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ THRB P10828 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ RECQL P46063 1/20 0.41
▸ EPHX1 P07099 1/20 0.41
▸ STS P08842 1/20 0.41
▸ TP53 P04637 1/20 0.41
▸ PTPN2 P17706 1/20 0.41
▸ PTPN1 P18031 1/20 0.41
▸ PTPN6 P29350 1/20 0.41
▸ FPR2 P25090 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23546345 0.88 GPR119 (0.42) NR3C1GPR119KDM4EMAPTTHRB
SCHEMBL23546418 0.86 GPR119 (0.42) NR3C1GPR119KDM4EMAPTTHRB
SCHEMBL22759303 0.85 NR3C1 (0.45) NR3C1GPR119KDM4EMAPTTHRB
SCHEMBL22759263 0.85 NR3C1 (0.47) NR3C1GPR119KDM4EMAPTTHRB
SCHEMBL26981264 0.83 TP53 (0.39) NR3C1GPR119HPGDRECQLEPHX1
SCHEMBL22875390 0.82 NR3C1 (0.45) NR3C1GPR119KDM4EMAPTTHRB
SCHEMBL22122136 0.82 NR3C1 (0.45) NR3C1GPR119KDM4EMAPTTHRB
SCHEMBL23546412 0.82 GPR119 (0.43) NR3C1GPR119KDM4EMAPTTHRB
SCHEMBL30318329 0.82 NR3C1 (0.40) NR3C1GPR119KDM4EEPHX1STS
SCHEMBL25898888 0.82 GPR119 (0.40) NR3C1GPR119KDM4EEPHX1STS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4514794-B1 FGFR2 INHIBITOR COMPOUNDS LILLY CO ELI (US) 2026-03-25 — — EP disclosed
US-20250263409-A1 FGFR2 INHIBITOR COMPOUNDS ELI LILLY AND COMPANY 2025-08-21 — — US disclosed
US-12351571-B2 Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases ARRAY BIOPHARMA INC. (US) 2025-07-08 — — US disclosed
EP-4514794-A1 FGFR2 INHIBITOR COMPOUNDS Eli Lilly and Company (US) 2025-03-05 — — EP disclosed
CN-119421882-A FGFR2 inhibitor compounds 伊莱利利公司 2025-02-11 — — CN disclosed
WO-2023212535-A1 FGFR2 INHIBITOR COMPOUNDS ELI LILLY AND COMPANY (US) 2023-11-02 — — WO disclosed
WO-2023212535-A1 FGFR2 INHIBITOR COMPOUNDS ELI LILLY AND COMPANY (US) 2023-11-02 — — WO disclosed
US-20230271968-A1 PYRAZOLOPYRIMIDINE COMPOUND USED AS ATR KINASE INHIBITOR BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) 2023-08-31 — — US disclosed
EP-4166556-A1 PYRAZOLOPYRIMIDINE COMPOUND USED AS ATR KINASE INHIBITOR Beijing Tide Pharmaceutical Co., Ltd. (CN) 2023-04-19 — — EP disclosed
US-20220081438-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES ARRAY BIOPHARMA INC. 2022-03-17 — — US disclosed
CN-113474337-A 7- ((3, 5-dimethoxyphenyl) amino) quinoxaline derivatives as FGFR inhibitors for the treatment of cancer 奥瑞生物药品公司 2021-10-01 — — CN disclosed
WO-2020131674-A1 7-((3,5-DIMETHOXYPHENYL)AMINO)QUINOXALINE DERIVATIVES AS FGFR INHIBITORS FOR TREATING CANCER ARRAY BIOPHARMA INC. (US) 2020-06-25 — — WO disclosed
WO-2020131674-A1 7-((3,5-DIMETHOXYPHENYL)AMINO)QUINOXALINE DERIVATIVES AS FGFR INHIBITORS FOR TREATING CANCER ARRAY BIOPHARMA INC. (US) 2020-06-25 — — WO disclosed
WO-2020131627-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES ARRAY BIOPHARMA INC. (US) 2020-06-25 — — WO disclosed
WO-2020131627-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES ARRAY BIOPHARMA INC. (US) 2020-06-25 — — WO disclosed
EP-2155201-B1 QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES NOVARTIS AG (CH) 2012-08-01 — — EP disclosed
US-8193189-B2 Quinoxaline derivatives as tyrosine kinase activity inhibitors NOVARTIS AG (CH) 2012-06-05 — — US disclosed
US-20100168062-A1 Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors NOVARTIS AG 2010-07-01 — — US disclosed
EP-2155201-A2 QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES Novartis Ag (CH) 2010-02-24 — — EP disclosed
WO-2008148867-A2 QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES NOVARTIS AG (CH) 2008-12-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168062-A1 Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors JAK2, JAK1, JAK3 NR3C1 2963/4885GPR119 841/4885KDM4E 1087/4885
US-20250263409-A1 FGFR2 INHIBITOR COMPOUNDS FGFR2, FGFR1, FGFR3 NR3C1 535/4885GPR119 582/4885KDM4E 915/4885
US-20230271968-A1 PYRAZOLOPYRIMIDINE COMPOUND USED AS ATR KINASE INHIBITOR ATR, CHEK1, CHEK2 NR3C1 1270/4885GPR119 1674/4885KDM4E 3465/4885
US-20220081438-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES FGFR1, FGFR4, FGFR3 NR3C1 870/4885GPR119 876/4885KDM4E 444/4885
US-12351571-B2 Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases FGFR3, FGFR4, FGFR1 NR3C1 1971/4885GPR119 2855/4885KDM4E 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.